These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33275721)

  • 1. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
    McClain K
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
    Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE; Parsons DW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathological and Clinical Findings in Cutaneous Manifestation of Erdheim-Chester Disease and Langerhans Cell Histiocytosis Overlap Syndrome Associated With the BRAFV600E Mutation.
    Liersch J; Carlson JA; Schaller J
    Am J Dermatopathol; 2017 Jul; 39(7):493-503. PubMed ID: 27898473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
    Friedman JS; Durham BH; Reiner AS; Yabe M; Petrova-Drus K; Dogan A; Pulitzer M; Busam KJ; Francis JH; Rampal RK; Ulaner GA; Reddy R; Yeh R; Hatzoglou V; Lacouture ME; Rotemberg V; Mazor RD; Hershkovitz-Rokah O; Shpilberg O; Goyal G; Go RS; Abeykoon JP; Rech K; Morlote D; Fidai S; Gannamani V; Zia M; Abdel-Wahab O; Panageas KS; Rosenblum MK; Diamond EL
    Br J Haematol; 2024 Jul; 205(1):127-137. PubMed ID: 38613141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Understanding and Management of Erdheim-Chester Disease.
    Kulkarni AM; Gayam PKR; Aranjani JM
    Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung.
    DeMartino E; Go RS; Vassallo R
    Clin Chest Med; 2016 Sep; 37(3):421-30. PubMed ID: 27514589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
    Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
    Kim S; Lee M; Shin HJ; Lee J; Suh YL
    Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
    Goyal G; Heaney ML; Collin M; Cohen-Aubart F; Vaglio A; Durham BH; Hershkovitz-Rokah O; Girschikofsky M; Jacobsen ED; Toyama K; Goodman AM; Hendrie P; Cao XX; Estrada-Veras JI; Shpilberg O; Abdo A; Kurokawa M; Dagna L; McClain KL; Mazor RD; Picarsic J; Janku F; Go RS; Haroche J; Diamond EL
    Blood; 2020 May; 135(22):1929-1945. PubMed ID: 32187362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
    Haroun F; Millado K; Tabbara I
    Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An overview of histiocytosis].
    Tojo A
    Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.